<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interleukin (IL)-23 and IL-27 are pro-inflammatory cytokines that share functional and structural similarities and may exert anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activities against solid and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we asked whether IL-23 and IL-27, alone or in combination, may act directly against human follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) cells </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we demonstrated for the first time that human primary FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cells expressed complete and functional IL-23 and IL-27 receptors (R) and that IL-23 and IL-27 exerted anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activities in vitro and in vivo through different and complementary mechanisms </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo studies using <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> /non-<z:mp ids='MP_0001261'>obese</z:mp> diabetic mice-injected subcutaneously with human SU-DHL-4 cell line revealed that IL-23 inhibited directly <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-cell proliferation, whereas IL-27 impaired the angiogenic program of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells resulting in strong reduction of cell growth </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, combined treatment of IL-23 and IL-27 amplified the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects in vivo as compared with administration of each cytokine alone </plain></SENT>
<SENT sid="5" pm="."><plain>These anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mechanisms were confirmed by in vitro experiments performed with primary <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>Our results strongly encourage the development of future clinical trials to evaluate the toxicity and efficacy of the IL-23 and IL-27 in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
</text></document>